AELIX Therapeutics Email Format

Biotechnology ResearchCatalonia, Spain2-10 Employees

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain, focused on developing a therapeutic vaccine to contribute to HIV cure or eradication efforts. It originated as a spin-off from HIVACAT, a Catalan public-private research consortium, and holds an exclusive worldwide license to develop and commercialize the HTI immunogen. The company operates within the biotechnology research field, pursuing strategies that aim to modulate the immune response to HIV.

Its customers and collaborators are other researchers and pharmaceutical partners involved in HIV cure research, seeking new therapeutic approaches. Historical milestones include a 2018 partnership with Gilead Sciences and, in 2021, the launch of an HIV vaccine candidate.

Sign up for free to view info

Company overview Employee directory